Azenta heads into its May 5 earnings call carrying the heaviest short interest it has seen in months, a building bearish footprint that arrived just as the stock broke back down from a sharp one-month rally.
Short sellers have been rebuilding aggressively. SI as a percentage of free float has risen to 15.2%, from roughly 10.5% at the start of April — a 46% jump in shares short over the month. The move accelerated mid-April, with the float short climbing from 10.7% on April 9 to 15.3% by April 27. That puts the current reading near the highest level seen across ORTEX's 30-day history window. The ORTEX short score confirms the pressure at 69, up from 64.5 in mid-April and approaching the kind of level associated with concentrated bearish conviction. Days to cover of 6.2 (per the latest FINRA fortnightly print) adds to the picture — it would take more than a week of average trading volume to unwind this position.
Notably, the borrow market tells a more relaxed story than the short interest figure suggests. Cost to borrow is near 0.50% annualised — effectively the minimum for a liquid US stock — and availability is adequate, with no signs of a squeeze in the lending pool. Short sellers have been able to build this position cheaply, without competing for scarce borrows. That means the short interest is not fragile in a squeeze sense; exits would be orderly rather than forced. Options traders are not adding much heat either. The put/call ratio is running at 0.19, essentially flat to its 20-day average, with a z-score near zero. There is no elevated demand for downside protection in the options market despite the short rebuild.
The Street is broadly constructive but increasingly cautious on valuation. The consensus rating is a buy, and the mean price target of $35.40 implies roughly 46% upside from the current $24.24. However, that headline number reflects a series of cuts rather than upgrades. Evercore ISI lowered its target from $45 to $35 in early April while keeping its Outperform rating — the most recent action in the dataset — and earlier in the year the same analyst had twice reduced targets following weak earnings. Needham and Jefferies have each trimmed as well, though all maintain positive ratings. TD Cowen holds a more cautious Hold with a $39 target. On valuation, the EV/EBITDA multiple has contracted meaningfully, down roughly 0.7 turns over the past 30 days to 6.9x, and the price-to-book now trades below 0.65x. EPS momentum factor scores are actually solid — 79th percentile over 30 days and 72nd over 90 days — suggesting estimate revisions have been more measured than the price action implies. EPS surprise ranks in just the 3rd percentile, however, pointing to a stock that has consistently disappointed on delivery.
The bull case centres on EBITDA margin expansion of 230 basis points year-on-year, gross margin improvement ahead, and operating leverage in both the Sample Management Solutions and Multiomics segments. The bear case is harder to dismiss: gross margins came in below consensus at 46.7%, SMS revenue was flat year-on-year at $86 million, and analysts have already revised FY26 and FY27 forecasts lower in response. Customer budget constraints and headwinds from the US government shutdown cloud the near-term demand picture. Among top holders, Conestoga Capital added 1.5 million shares in the latest quarter — a material move that accounts for around 6% of shares — while Congress Asset Management added 860,000 shares. Institutional support is present but not unanimous.
The last earnings print on February 4 delivered a punishing -24.5% one-day move and a -17.5% five-day follow-through. With shorts at multi-month highs and peers RGEN and PACB both off 11.5% and 8.7% on the week respectively, the sector backdrop is fragile. The May 5 print is the moment where the tension between a deeply discounted valuation, a credible margin expansion story, and a heavily-rebuilt short book gets resolved.
See the live data behind this article on ORTEX.
Open AZTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
